Description of Research: James Riddell

HIV/AIDS

Dr. Riddell’s main area of research interest is to find ways to improve the clinical care of patients with immunocompromising conditions such as HIV/ADS and the optimal management of opportunistic infections. Dr. Riddell is the Principal Investigator (PI) of the CPCRA SMART study at the University of Michigan site. The SMART study is a national NIH sponsored project designed to determine if antiretroviral therapy may be used effectively in a more conservative manner in patients infected with HIV to minimize exposure to medication and potentially minimize side effects. Dr. Riddell has also been the PI for a variety of pharmaceutical industry sponsored studies involved with the development of new antiretroviral medications such as tipranavir and capravirine. He also is the PI for a pharmaceutical industry sponsored multicenter trial evaluating the mechanisms of resistance for the new antiretroviral drug atazanavir. Dr. Riddell is involved in two single site clinical studies analyzing HIV resistance in antiretroviral naïve patients and evaluating long term outcomes in patients with the MAC immune reconstitution inflammatory syndrome. Dr. Riddell is also completing a study evaluating the relevance of asymptomatic lactic acidosis which can occur in patients taking antiretroviral medication. The future goal of our HIV/AIDS program is to become more involved in large clinical trials to benefit our patients and contribute to optimizing the clinical care of patients infected with HIV. Dr. Riddell has recently applied to become part of the INSIGHT clinical trials network which is an international group with the goal of solving various clinical problems faced by people infected with HIV.

INFECTIONS IN TRANSPLANT PATIENTS
Our group is developing a transplant infectious disease consult service to both better serve the clinical needs of these complex patients and provide a platform for clinical research. Currently, a consult service staffed by physicians with a specific interest in infections in the immunocompromised host is consulting on hematopoietic stem cell recipients with infectious complications of their transplant. In conjunction with the Bone Marrow Transplant service, we are developing clinical protocols to manage and prevent infections in this population. We hope to expand this service soon to include recipients of solid organ transplants.

Recent publications:

Riddell, J; Chenoweth, CE; Kauffman, CA; Disseminated Sceodosporium apiospermum infection in a previously healthy woman with HELLP syndrome. Mycoses, 47:442-6, 2004.

Malani PN, DePestel, DD, Riddell J, Bickley, S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 25: 690-697, 2005.

Washer LL, Riddell IV J, Rider J, Chenoweth CE. Mycobacterium neoaurum bloodstream infections: report of 4 cases and review of the literature. Clin Infect Dis 2007; 45:e10-13.

Cinti, SK; Gandhi, T; Riddell, J. Non-AIDS-defining cancers: Should antiretroviral therapy be initiated earlier? AIDS Read 18 (1): 18, 2008.

Riddell J IV, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes - art. no. 50. J Translat Med 5: 50, 2007.